Sun Pharmaceutical Industries, an international, integrated, speciality pharmaceutical company, witnessed a sharp fall in share price on Tuesday after the company said that the company's FY16 revenue could remain flat or show a decline over FY15 due to meger of Ranbaxy.

'Revenues are expected to remain low as the company expects to incur certain integration charges in order to generate long-term synergies from the Sun Pharma-Ranbaxy merger,' the company said.

In addition to the revenue impact, the company expects that profits may also be adversely impacted due to certain expenses/ charges arising out of integration as well as remedial actions.

'Our target for the synergy benefits from the Ranbaxy acquisition has increased by 15-20% as compared to our original target of USD 250 million by FY18,' the company said.

'Sun Pharmaceuticals will continue to allocate significant resources to R&D in order to strengthen the specialty pipeline including patented products and complex generics,' the company said.

Shares of Sun Pharmaceutical Industries closed at Rs 805.30, down Rs 141.5, or 14.95% at the Bombay Stock Exchange (BSE) on Tuesday. The scrip has touched an intra-day high of Rs 852.15 and low of Rs 799.05. Total volume of shares traded on the bourses today was higher by 2,113.35% to 35,650,465 compared with 22-day average volume of 1,610,703.